Fuller & Thaler Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Fuller & Thaler Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-200	Closed	-$69K	–	673
2018 Q2	$69K	Hold	200	–	–	﹤0.01%	652
2018 Q1	$69K	Buy	+200	New	+$69.6K	﹤0.01%	638
2017 Q1	–	Sell	-700	Closed	-$257K	–	743
2016 Q4	$257K	Hold	700	–	–	﹤0.01%	354
2016 Q3	$281K	Buy	700 +300	+75%	+$120K	﹤0.01%	303
2016 Q2	$140K	Buy	+400	New	+$154K	﹤0.01%	370
2015 Q3	–	Sell	-300	Closed	-$153K	–	741
2015 Q2	$153K	Sell	300 -200	-40%	-$97.6K	﹤0.01%	453
2015 Q1	$226K	Sell	500 -700	-58%	-$297K	0.01%	393
2014 Q4	$492K	Buy	1,200 +500	+71%	+$197K	0.02%	316
2014 Q3	$252K	Buy	700 +200	+40%	+$67K	0.01%	398
2014 Q2	$141K	Sell	500 -1,100	-69%	-$326K	0.01%	512
2014 Q1	$480K	Buy	1,600 +1,000	+167%	+$308K	0.02%	322
2013 Q4	$165K	Hold	600	–	–	0.01%	431
2013 Q3	$188K	Sell	600 -26,100	-98%	-$6.87M	0.01%	389
2013 Q2	$6M	Buy	+26,700	New	+$6.22M	0.42%	102

Other funds holding REGN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fuller & Thaler Asset Management's REGN Position: Q3 2018 in Review

Fuller & Thaler Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2018, closing a stake of 200 shares — an estimated $69K sold.

Fuller & Thaler Asset Management first reported a position in REGN in Q2 2013 and held it in 14 quarters. The position peaked at $6M in Q2 2013. 644 funds tracked by Wall St. Rank hold REGN as of Q3 2018.

Fuller & Thaler Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Fuller & Thaler Asset Management sold 200 Regeneron Pharmaceuticals shares in Q3 2018, an estimated $69K.
Fuller & Thaler Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 14 quarters.
Fuller & Thaler Asset Management's Regeneron Pharmaceuticals position peaked at $6M in Q2 2013.
644 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2018.

Based on Fuller & Thaler Asset Management's 13F filing for Q3 2018, filed 13 Nov 2018.